| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A409120-1ml |
1ml |
现货  |
|
| 英文别名 | 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo- |
|---|---|
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | ABBV-744 |
| 生化机理 | ABBV-744 是一种 BDII 选择性 BET 溴域抑制剂，可抑制 BRD2、BRD3 和 BRD4。它被开发用于治疗急性髓细胞白血病和癌症。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Information ABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers. ABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with >250-fold differential binding preference for BDII over BDI and excellent drug-like properties. ABBV-744 is also a potent and selective inhibitor of the AR (androgen receptor) transcription pathway. In vivo In vivo, doses of ABBV-744 at fractions of its maximum tolerated dose (MTD) induces tumor growth inhibition in AML and prostate cancer xenograft models that were comparable to those observed with ABBV-075 when dosed at its MTD. cell lines： Concentrations： Incubation Time： Powder Purity:≥99% |
| ALogP | 4.36 |
|---|---|
| hba_count | 3 |
| HBD Count | 2 |
| Rotatable Bond | 6 |
| 分子类型 | 小分子 |
|---|---|
| Canonical SMILES | CCNC(=O)C1=CC2=C([NH]1)C(=O)N(C)C=C2C3=C(OC4=C(C)C=C(F)C=C4C)C=CC(=C3)C(C)(C)O |
| 分子量 | 491.55 |
| Reaxy-Rn | 31981858 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=31981858&ln= |
| DMSO(mg / mL) Max Solubility | 98 |
|---|---|
| DMSO(mM) Max Solubility | 199.37 |
| Water(mg / mL) Max Solubility | <1 |
| Reaxy-Rn | 31981858 |
|---|---|
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=31981858&ln= |
| Concentration | 9-11（mmol/L） |
|---|---|
| NMR Spectrum 1H | Conforms to structure |
首页
400-620-6333
